## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting P Rowinsky Eric K	2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_Director  10% Owner					
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301		3. Date of Earliest Transaction (Month/Day/Year) 01/01/2022					Office	r (give title belo	ow)	Other (specify be	low)	
(Street) BAY HARBOR ISLAND, FL 33154		4. If Amendment, Date Original Filed(Month/Day/Year)					-	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State)	(Zip)	Ta	ıble I - No	n-Deriv	vative Sec	curities	Acqui	red, Dispo	osed of, or l	Beneficially (	Owned	
1.Title of Security (Instr. 3)		2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D)	Reported Transaction(s)			Ownership Form:	Beneficial
			Code	V	Amount	(A) or (D)	Price	(Instr. 3 a	nd 4)			Ownership (Instr. 4)
Common Stock, par value \$0.001	01/01/2022		A		100,000	A	\$ 0	820,000 (2)			D	
		Derivative Securiti		the fo	orm displ sposed of,	or Bene	currer eficiall	itly valid		spond unle trol numbe		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise (Month/E Derivative Security	ition 3A. Deemed Execution Da ay/Year) any	e, if Transaction Code of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Dat and E (Mont	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Unde Secu	tle and ount of erlying rities r. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security: Direct (D or Indirec	Beneficia Ownershi (Instr. 4)
			(Instr. 3,					Amount		(mou. 1)	(msu. 4)	

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Rowinsky Eric K C/O FORTRESS BIOTECH, INC. 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLAND, FL 33154	X					

# **Signatures**

/s/ Samuel Berry, Attorney-in-Fact	04/29/2022
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) One-third of the shares will vest on each January 1, 2023, 2024 and 2025, subject to continued service.
- (2) The total holdings include 100,000 shares of deferred restricted stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.